Castle Creek Biosciences

08/30/2022

Hereditary tyrosinemia type 1 (HT1) is a rare inborn error of metabolism of the liver, affecting 1 in 100,000 live births. At Castle Creek, we are developing an in vivo gene therapy program to address this genetic disorder.

Recently published research in Nature Communications found that our lead in vivo gene therapy candidate resolved biochemical and hepatic histological markers of HT1 in a large animal model of the disease. The study was conducted by Mayo Clinic researchers.

Read more here:

The cell and gene therapy company’s lead in vivo candidate uses lentiviral vector delivery to correct metabolic disorder in large animal model of hereditary tyrosinemia type-1

07/29/2022

We’re advancing our novel gene therapy development programs for genetic skin disorders and metabolic liver diseases, including hereditary tyrosinemia type 1 . HT1 is a rare inborn error of metabolism of the liver, affecting 1 in 100,000 live births.

Learn more from NOTA, the Network of Tyrosinemia Advocates: https://notacares.org

07/18/2022

Attending the ? We are on-site and can answer questions about the RDEB clinical study program for recessive dystrophic .

For more information on the current clinical study, visit https://defi-rdeb.com/ debra of America

07/17/2022

The debra of America Care Conference begins today! We are honored to be a sponsor of this multi-day event, designed for families and caregivers to engage with other EB families and professionals. Members of our executive leadership team are attending, and look forward to meeting with individuals living with EB and hearing about their experiences.

Find details about the conference: https://www.debra.org/debra-hosted-events/debra-care-conference

06/30/2022

The Society for Pediatric Dermatology 47th Annual Meeting will be held in Indianapolis from July 7-10. SPD is focused on advancing the education and research of pediatric skin disorders and providing advocacy services in support of patients and families. See you there!

To review the schedule, speakers, and session topics, visit https://pedsderm.net/meetings/annual-meeting/ -CourseDirectors

06/24/2022

This month we join our colleagues and industry partners in celebrating ! At Castle Creek Biosciences, we believe drives innovation, and that a variety of backgrounds and perspectives are essential to creating a real impact. We’re committed to a workforce who are passionate about making a difference for patients and families living with genetic diseases.

06/19/2022

Happy ! Celebrating the incredible dads everywhere and especially those on our Castle Creek Biosciences team. We are inspired by your spirit and strength and appreciate everything you do!

05/30/2022

This , we take time to remember those who have served and sacrificed for our freedom.

05/25/2022

Today we announced $112.8M in financing. This funding will accelerate the expansion of our novel cell and gene therapy development programs, supporting the expected completion of our Phase 3 study for recessive dystrophic epidermolysis bullosa ( ), and advancing our plans to submit an Investigational New Drug (IND) application to the FDA for hereditary tyrosinemia type 1 (HT1).

To learn more, see our press release: https://castlecreekbio.com/castle-creek-biosciences-raises-112-8-million-to-advance-novel-gene-therapies-and-expand-pipeline/

05/19/2022

Many thanks to Society for Investigative Dermatology (SID) for planning this week’s 2022 Annual Meeting, a gathering of exceptional experts in discussing the latest in the science of skin health and disease.

For details on , taking place in Portland, Oregon, visit https://www.sidannualmeeting.org/

05/17/2022

We have two abstracts accepted for encore presentations this week at highlighting our clinical program in recessive dystrophic .

Our team is looking forward to sharing this important data with the scientific community and showcasing our expertise in cell and development for rare genetic diseases.

05/09/2022

Nurses play an essential role in supporting patients and families during some of their most challenging moments. This week in recognition of , we express our gratitude for their enduring strength, compassion, and commitment to care.

If you are a member of the community, check out the EB Nurse Educator Program, created by debra of America in 2002, which provides trusted tips and resource for individuals with EB individuals and their families, among others. Learn more: https://www.debra.org/get-help/eb-nurse-educator-program